Plus   Neg

6 Top Gainers In Healthcare Sector (HOTH, CHMA, TRPX…)

pharmaup july23 lt

The following are some of today's top gainers in the healthcare sector.

1. Hoth Therapeutics Inc. (HOTH)

Hoth Therapeutics is a development-stage biopharmaceutical company developing therapeutics for patients suffering from indications such as atopic dermatitis and dermatological and chronic wound disorders.

Gained 58.82% to close Tuesday's (July 23) trading at $6.75.

News: The Company announced positive initial results of its Pilot Study of BioLexa Platform's application on diabetic skin ulcers in an animal model. Hoth has exclusive worldwide rights to the BioLexa Platform.

Commenting on the results, Robb Knie, CEO of Hoth Therapeutics, said, "Preliminary results indicated that, as a wound care product, Biolexa performed extremely well in a mouse model of diabetic ulcers. Hoth is excited about the next phase of our pilot program and look forward to sharing results upon the completion of the next module."

2. Therapix Biosciences Ltd. (TRPX)

Therapix Biosciences is a Canada-based specialty clinical-stage pharmaceutical company developing unique cannabinoid technologies for the treatment of central nervous system disorders.

Gained 47.83% to close Tuesday's trading at $3.40.

News: The Company has signed a letter of intent for a proposed merger with Destiny Biosciences Global Corp. in a stock for stock transaction.

The transaction values Therapix at approximately US$48 million plus any cash on hand at the closing, and the combined company at about US$151 million. The market cap of Therapix based on Tuesday's closing price of $3.40 is US$11.921 million.

3. Microbot Medical Inc. (MBOT)

Microbot Medical is a medical device company specializing in the design and development of transformational micro-robotic medical technologies.

Gained 31.63% to close Tuesday's trading at $6.95.

News: No news

Recent event:

On January 14, 2019, the Company announced encouraging results from an independent in-vitro study of its Self-Cleaning Shunt, or SCS, for treating Hydrocephalus, also known as "water in the brain".

Near-term Catalyst:

-- Completion of a pivotal pre-clinical study to further evaluate the safety and efficacy of the SCS being performed at Washington University in St. Louis School of Medicine and Wayne State University is expected in the third quarter of 2019.
-- The FDA regulatory pre-submission request for the SCS is expected to be finalized in the second half of 2019.

4. Adynxx Inc. (ADYX.OB)

Adynxx is a clinical-stage biopharmaceutical company developing novel, disease-modifying products for the treatment of pain and inflammation.

Gained 29.54% to close Tuesday's trading at $2.85.

News: No news

Recent event:

On June 13, 2019, the Company's common stock began trading on the OTC Markets Pink market tier, following the receipt of Nasdaq delisting notice.

5. Achillion Pharmaceuticals Inc. (ACHN)

Achillion Pharma is a clinical-stage biopharmaceutical company developing orally-administered, small molecule, Factor D inhibitors for the treatment of Paroxysmal Nocturnal Hemoglobinuria, C3 Glomerulopathy and immune complex membranoproliferative glomerulonephritis.

Gained 28.88% to close Tuesday's trading at $3.57. This is the second straight day of gain for the stock.

News: No news

Recent event:

On July 22, 2019, the Company announced positive results from its Phase 1 multiple ascending dose (MAD) study with ACH-5228 in healthy volunteers outside of the United States. The news sent the stock up 16.39% to close yesterday's trading at $2.77.
ACH-5228 is expected to move into phase II clinical trials in multiple diseases.

Near-term Catalyst:

The Company expects to submit an IND application to the U.S. FDA supporting clinical development for ACH-5228 in the fourth quarter of 2019.

6. Chiasma Inc. (CHMA)

Chiasma is a clinical-stage biopharmaceutical company developing drugs for rare and serious chronic diseases.

The Company's lead drug candidate is MYCAPSSA (octreotide capsules), being developed as a maintenance treatment for adult patients with acromegaly.

Gained 26.77% to close Tuesday's trading at $7.86.

News: The Company announced positive top-line data from its pivotal phase III clinical trial of MYCAPSSA for the maintenance treatment of adults with acromegaly, dubbed CHIASMA OPTIMAL.

The trial met the primary endpoint - with 58% of the patients on MYCAPSSA maintaining their IGF-1 response compared to 19% of the patients on placebo.

Near-term Catalyst:

The Company plans to submit an NDA for MYCAPSSA for the maintenance treatment for adult patients with acromegaly by the end of this year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT